Olaparib in the Treatment of BRCA1/2 Unmutated and BRCA1 Promoter Methylated Recurrent and Metastatic Triple-negative Breast Cancer

Status:
Not yet recruiting

Trial end date:
2024-09-01

Target enrollment:

Participant gender:

This is an open-label, single-arm, single-center,exploratory clinical study.

Phase 2

Hebei Medical University Fourth Hospital

Olaparib